Leila Tchelebi

Dr. Leila Tchelebi

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Cancer Epidemiology
Verified
Journal Article
Closed access
SHSamantha R Horn
Samantha R Horn
KSKelsey C Stoltzfus
Kelsey C Stoltzfus
ELEric J Lehrer
Eric J Lehrer
LDLaura A. Dawson
Laura A. Dawson
LTLeila Tchelebi
Leila Tchelebi
NZNicholas G Zaorsky
Nicholas G Zaorsky

1 January 2021 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
ELEric Lehrer
Eric Lehrer
RSRaj Singh
Raj Singh
MWMing Wang
Ming Wang
VCVernon M. Chinchilli
Vernon M. Chinchilli
DTDaniel M. Trifiletti
Daniel M. Trifiletti
NZNicholas G. Zaorsky
Nicholas G. Zaorsky
Local therapies have previously had limited utility in the context of metastatic cancer owing to an inability to account for radiologically occult sites of disease. The traditional treatment of patients with metastatic solid tumors involved the use of systemic therapies with the goal of delaying disease progression and extending overall survival (OS).1,2 In 1995, Hellman and Weichselbaum3 at the University of Chicago formally defined the oligometastatic paradigm. This paradigm suggests that in certain tumors, anatomic and physiologic factors may limit and concentrate the number of metastases to single or few organs. This concept has been recently expanded in the context of patients with synchronous oligometastatic disease or those with oligoprogressive cancer (defined as patients with the majority of the disease being stable or responding to therapy with a limited number of sites exhibiting progression).4 Subsequent work building on this hypothesis has found that distinct molecular subgroups exist that, in combination with clinical risk factors, define subpopulations who may preferentially benefit from aggressive local therapy and potentially delay tumor seeding of other sites and the development of more aggressive phenotypes.5


1 October 2011 in Kidney International
Verified
Journal Article
Open access
PDF file
OZOlga Zhdanova
Olga Zhdanova
SSShekhar Srivastava
Shekhar Srivastava
LDLie Di
Lie Di
ZLZhai Li
Zhai Li
LTLeila Tchelebi
Leila Tchelebi
ESEdward Y. Skolnik
Edward Y. Skolnik
Micro-RNAs (miRNAs) are short (average 22 nucleotides) noncoding regulatory RNAs that inhibit gene expression by targeting complementary 3′-untranslated regions of protein-encoding mRNAs for translational repression or degradation. miRNAs play key roles in both the function and differentiation of many cell types. Drosha and Dicer, two RNAase III enzymes, function in a stepwise manner to generate a mature miRNA. Previous studies have shown that podocyte-specific deletion of Dicer during development results in proteinuric renal disease and collapsing glomerulopathy (CG); however, Dicer has functions other than the generation of miRNAs. Here we found that the podocyte-specific deletion of Drosha results in a similar phenotype to Dicer mutants, confirming that the Dicer mutant phenotype is due to the loss of miRNAs. Moreover, the inducible deletion of Drosha in 2- to 3-month-old mice (Tet-On system) resulted in CG. Thus, continuous generation of miRNAs are required for the normal function of mature podocytes and their loss leads to CG. Identifying these miRNAs may provide new insight into disease pathogenesis and novel therapeutic targets in various podocytopathies.

24 July 2014
Verified
Book Chapter
Closed access
PDF file
LTLeila Tchelebi
Leila Tchelebi
HAHani Ashamalla
Hani Ashamalla
PGPaul R. Graves
Paul R. Graves

1 July 2020 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
LTLeila Tchelebi
Leila Tchelebi
KHKarin Haustermans
Karin Haustermans
MSMarta Scorsetti
Marta Scorsetti
AHAli Hosni
Ali Hosni
FHFlorence Huguet
Florence Huguet
KGKaryn A. Goodman
Karyn A. Goodman